layer1-background

News

 
News
  Date Title View
Dec 24, 2013
PALO ALTO, Calif., Dec. 24, 2013 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX) today announced that Wendell Wierenga, Ph.D., has joined its board of directors. "We are excited that Wendell has accepted our offer to join our board, and we will benefit greatly from his leadership as we advance our Phase 2b clinical trials," said Linda Grai...
Dec 17, 2013
PALO ALTO, Calif., Dec. 17, 2013 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX) today announced that it has entered into a Technology Transfer and License Agreement with the Roche Group, including the Research and Early Development arms of both Genentech and Roche, for rights to its Macrocyclic Template Chemistry (MATCH™) discovery plat...
Dec 11, 2013
PALO ALTO, Calif., Dec. 11, 2013 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX) today announced that David S. Moore, its chief business officer, will be leaving Ocera to pursue other opportunities. Mr. Moore was a former member of the management team at Tranzyme and continued his employment with Ocera following the merger of Ocera and Tranzym...
Nov 26, 2013
PALO ALTO, Calif., Nov. 26, 2013 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Linda Grais, M.D., president and chief executive officer, plans to present at the 25th Annual Piper Jaffrey Healthcare Conference taking place at t...
Nov 13, 2013
PALO ALTO, Calif., Nov. 13, 2013 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a biopharmaceutical company focused on innovative therapeutics for orphan liver disease, announced today financial results for the three and nine months ended September 30, 2013.Ocera Business Updates Since the start of the third quarter, Ocera's busine...
Nov 6, 2013
SAN DIEGO, Nov. 6, 2013 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a biopharmaceutical company focused on innovative therapeutics for orphan liver disease, announced today that it has obtained commitments to purchase common stock and warrants in a private placement. Gross proceeds from the private placement are expected to be $28 m...
Sep 25, 2013
SAN DIEGO, Sept. 25, 2013 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Linda Grais, M.D., president and chief executive officer, will present at the 12th Annual BIO Investor Forum taking place at the Palace Hotel in San Franc...
Sep 17, 2013
SAN DIEGO, Sept. 17, 2013 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX), a clinical stage biopharmaceutical company focusing on acute and chronic orphan liver diseases, today announced a restructuring plan involving the closure of operations in its Sherbrooke, Quebec facility effective November 11, 2013. The Sherbrooke facility housed 17 emp...
Sep 3, 2013
SAN DIEGO, Sept. 3, 2013 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Jeryl L. Hilleman has been appointed chief financial officer effective September 3, 2013. Ms. Hilleman will replace Dana McGowan who will continue with the...
Aug 13, 2013
SAN DIEGO, Aug. 13, 2013 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. ("Ocera" or the "Company") (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on the development and commercialization of proprietary compounds to treat acute and chronic orphan liver diseases, today announced its financial results and business update for the secon...
FirstPrevious
...
8
NextLast
= add release to Briefcase